OVERVIEW

FOX04‑DRI (Proxofim) 10 mg is a synthetic D‑retro‑inverso peptide developed for research into cellular senescence and longevity pathways. It is engineered from a sequence of the forkhead box protein O4 (FOXO4) and designed to disrupt the interaction between FOXO4 and the tumor suppressor protein p53 — a mechanism that helps some non‑dividing, aged (“senescent”) cells avoid programmed cell death. In senescent cells, FOXO4 binds p53 and sequesters it in the nucleus, preventing apoptosis. FOX04‑DRI competitively displaces this interaction, freeing p53 to trigger apoptosis selectively in senescent cells while sparing many healthy cells, making it a valuable tool in laboratory models exploring senolytic strategies, aging biology, and regeneration. Researchers use it to study how clearing senescent cell populations affects inflammation, tissue homeostasis, and age‑related dysfunction in controlled in vitro and animal systems.

Despite its promise in the laboratory, FOX04‑DRI is not approved by the U.S. Food and Drug Administration or other regulatory agencies for therapeutic use in humans. The peptide is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease, and its safety, effective dosing, and long‑term effects in humans remain unestablished. Most supporting evidence comes from preclinical studies rather than clinical trials, and self‑administration outside controlled research environments carries potential safety and ethical concerns. Individuals interested in aging, senescence, or regenerative therapies should consult qualified healthcare professionals and rely on evidence‑based approaches rather than experimental peptides.